PHPN Stock Chart & Stats
€2.94
-€0.08(-2.65%)
At close: 4:00 PM EDT
€2.94
-€0.08(-2.65%)
Day’s Range― - ―
52-Week Range€1.61 - €5.80
Previous CloseN/A
Volume0.00
Average Volume (3M)23.00
Market Cap
€272.71M
Enterprise Value€307.34
Total Cash (Recent Filing)€14.11M
Total Debt (Recent Filing)€135.72M
Price to Earnings (P/E)―
Beta-0.44
Next Earnings
Aug 17, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding100,849,650
10 Day Avg. Volume0
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.52Price Target Upside223.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Clarity (FDA Phase 3)Agreement with the FDA on a primary endpoint and a traditional full-approval pathway materially reduces regulatory execution risk. This clarity enables a single adequate, well-controlled Phase 3 trial design, improves ability to recruit patients, and strengthens the company’s case when seeking strategic or financial partners over the next several months.
Balance Sheet Improvement Via Debt ConversionEliminating roughly $105.8M of debt materially reduces leverage and interest obligations, improving financial flexibility. The conversion signals sustained insider support, shrinks near-term default risk, and preserves an undrawn $10M facility to help fund Phase 3 execution or partnership activities over the coming months.
Improving Cash Burn TrendMaterial year-over-year reduction in cash burn reflects tighter cost control and more efficient operations. While still negative, the improving trajectory extends runway versus prior years and reduces near-term financing needs, increasing the chance management can advance Phase 3 activities without immediate dilutive raises.
Bears Say
No Commercial RevenueThe company generates no product revenue and posts persistent net losses, leaving it fully dependent on capital markets or partner deals to fund operations. This structural reliance increases dilution and execution risk during multi-year clinical development, making financing availability a critical long-term vulnerability.
Historically Weak Balance SheetA deeply negative equity position and previously high leverage constrain strategic optionality and borrowing capacity. Even with recent conversions, the legacy capital structure indicates a history of reliance on external funding; limited tangible assets reduce collateral availability and heighten vulnerability if additional capital is needed.
Single Asset / Small ScaleWith one primary therapeutic program and a very small team, the company lacks diversification and internal scale. Clinical outcomes for belapectin are binary drivers of value; failure or delays would disproportionately impair prospects and revenue pathways, increasing long-term dependency on partners for development and commercialization.
Galectin Therapeutics News
PHPN FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was €1.61 and its highest was €5.80 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is €272.71M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Aug 17, 2026 which is in 5 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on May 15, 2026. The company reported -€0.069 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.08.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 100,849,650 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -€0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.383%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:PHPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.52 (223.81% Upside)
€9.52 (223.81% Upside)
Blogger Sentiment
Bullish
DE:PHPN Sentiment 100%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
PHPN Stock 12 Month Forecast
Average Price Target
€9.52
▲(223.81% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―